Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Long. G.
Right arrow Articles by Ferrari, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Long. G.
Right arrow Articles by Ferrari, A. C.
[Cancer Research 61, 7544-7551, October 15, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Overexpressed Androgen Receptor Linked to p21WAF1 Silencing May Be Responsible for Androgen Independence and Resistance to Apoptosis of a Prostate Cancer Cell Line1

Long. G. Wang, Liliana Ossowski and Anna C. Ferrari2

Department of Medicine, Division of Medical Oncology and D. H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029

An androgen-independent (AI) prostate cancer cell line, derived recently from an LNCaP cell line maintained in androgen-poor conditions, has properties resembling a subgroup of advanced prostate cancers in that it has an overexpressed androgen receptor (AR), undetectable levels of p21WAF1 and prostate-specific antigen, and is resistant to apoptosis. The loss of prostate-specific antigen expression but not the p21WAF1 is attributable to gene silencing by hypermethylation. The high AR and undetectable p21WAF1 of AI cells, and lower AR but highly expressed p21WAF1 of androgen-dependent parental LNCaP cells, suggest a possibility of a functional link between these two proteins. Therefore, we examined the impact the modulation of AR will have on the expression of p21WAF1. Treatment of androgen-dependent cells with an androgen agonist, R1881, increased the AR protein level, whereas it simultaneously reduced the endogenous p21WAF1-protein 8-fold and the activity of a transiently transfected p21-promoter-reporter 10-fold. The down-regulation of p21WAF1 promoter appeared to be ARE mediated, dependent on AR, and not cell-type specific. Furthermore, a reduction of the AR level in AI cells by AR-antisense oligonucleotide increased the p21WAF1 promoter-reporter activity by ~4-fold, confirming a functional link between these two proteins. A strong, direct induction of p21WAF1 expression achieved by treatment of AI cells with trichostatin A produced a partial reversion of the AI phenotype evidenced by increased sensitivity of these cells to paclitaxel-induced apoptosis. Moreover, a reduction of AR level by antisense treatment, which also increased p21WAF1 expression, partially restored the androgen dependence of AI cells for growth. The functional link between AR dosage and p21WAF1 expression suggests that therapeutic reduction of AR protein in advanced prostate cancers with elevated AR levels may re-establish their hormone dependence and improve therapeutic response to repeated hormonal ablation and/or induction of apoptosis.




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. G. Wang, E. M. Johnson, Y. Kinoshita, J. S. Babb, M. T. Buckley, L. F. Liebes, J. Melamed, X.-M. Liu, R. Kurek, L. Ossowski, et al.
Androgen Receptor Overexpression in Prostate Cancer Linked to Pur{alpha} Loss from a Novel Repressor Complex
Cancer Res., April 15, 2008; 68(8): 2678 - 2688.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Ko, L. Shi, S. Kim, C. S. Song, and B. Chatterjee
Interplay of Nuclear Factor-{kappa}B and B-myb in the Negative Regulation of Androgen Receptor Expression by Tumor Necrosis Factor {alpha}
Mol. Endocrinol., February 1, 2008; 22(2): 273 - 286.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. D. Dinnen, L. Drew, D. P. Petrylak, Y. Mao, N. Cassai, J. Szmulewicz, P. Brandt-Rauf, and R. L. Fine
Activation of Targeted Necrosis by a p53 Peptide: A NOVEL DEATH PATHWAY THAT CIRCUMVENTS APOPTOTIC RESISTANCE
J. Biol. Chem., September 14, 2007; 282(37): 26675 - 26686.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. K. Hess-Wilson, H. K. Daly, W. A. Zagorski, C. P. Montville, and K. E. Knudsen
Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult
Cancer Res., December 15, 2006; 66(24): 11998 - 12008.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
T. Inoue, T. Yoshida, Y. Shimizu, T. Kobayashi, T. Yamasaki, Y. Toda, T. Segawa, T. Kamoto, E. Nakamura, and O. Ogawa
Requirement of Androgen-Dependent Activation of Protein Kinase C{zeta} for Androgen-Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen-Independent Cells
Mol. Endocrinol., December 1, 2006; 20(12): 3053 - 3069.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M.R. Bhuiyan, Y. Li, S. Banerjee, F. Ahmed, Z. Wang, S. Ali, and F. H. Sarkar
Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
Cancer Res., October 15, 2006; 66(20): 10064 - 10072.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L.G. Wang, X.M. Liu, and J.W. Chiao
Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate
Carcinogenesis, October 1, 2006; 27(10): 2124 - 2132.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. V. Kalin, I-C. Wang, T. J. Ackerson, M. L. Major, C. J. Detrisac, V. V. Kalinichenko, A. Lyubimov, and R. H. Costa
Increased Levels of the FoxM1 Transcription Factor Accelerate Development and Progression of Prostate Carcinomas in both TRAMP and LADY Transgenic Mice
Cancer Res., February 1, 2006; 66(3): 1712 - 1720.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Wang, H. Deng, I. Basu, and L. Zhu
Induction of Androgen Receptor-Dependent Apoptosis in Prostate Cancer Cells by the Retinoblastoma Protein
Cancer Res., February 15, 2004; 64(4): 1377 - 1385.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi
Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis
Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.